In this edition of Investor Eye, Medtech Insight spoke to Kyp Sirinakis, managing partner at Epidarex Capital, a transatlantic fund investing in emerging life science hubs in the US and UK. The firm recently launched a new UK fund, Epidarex Capital III, for innovative UK start-ups.
Venture fund Epidarex Capital likes to think of itself as an "innovation hunter" says co-founder and managing partner, Kyp Sirinakis.
Launched in 2010 by Sirinakis and partner Sinclair Dunlop, Maryland-based Epidarex focuses on investing in early-stage life sciences
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.
Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.
